Future validation using in vivo models, such as patient‐derived xenografts or genetically engineered mouse models, alongside correlative analyses of METTL14 expression/activity in clinical NPC specimens, will be essential to confirm the translational relevance of these observations. This evidence concerns the gene METTL14 and nasopharyngeal carcinoma.